Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Erlotinib may cause scarring hair loss.

This review highlights the potential of amphiregulin as a therapeutic target, noting its role in both fibrotic and malignant diseases, and discusses promising early findings but reports no new clinical results.

This study found that inhibiting EGFR signaling in mice can prevent alopecia caused by cyclophosphamide treatment, highlighting its potential role in managing chemotherapy-induced hair loss.

This case report describes how discontinuing the EGFR inhibitor gefitinib led to rapid improvement of erosive scalp pustules in a woman with non-small-cell lung cancer, despite previous antibiotic and steroid treatment failures.

This case report describes the management of PRIDE complex, a skin and hair condition associated with EGFR inhibitor treatment like cetuximab, emphasizing that it does not require stopping the medication.

LRIG1 protein affects hair growth by regulating skin receptors, leading to hair loss when overexpressed.

This study found that epidermal growth factor significantly enhances the proliferation of hair follicle-derived mesenchymal stem cells through the EGFR/ERK and AKT pathways, without involving the STAT3 pathway.

This study found that in mice, hyper-activated JAK-STAT1 signaling due to EGFR inhibitor treatment leads to scarring alopecia, but JAK1/2 inhibition can restore hair follicle immune privilege and promote new hair growth.

This study found that EGFR inhibitors and ligands did not significantly affect the expression of inflammatory biomarkers in cultured sebocytes, except for a notable increase in IL-1 expression with EGF treatment.

This study demonstrated that disrupting EGFR signaling in mice leads to immune sensitivity compromising the hair follicle's protective environment, but JAK1/2 inhibition can restore this immune privilege and stimulate hair growth, suggesting a potential therapy for scarring hair loss diseases like cicatricial alopecia.

This review discusses the cutaneous side effects of chemotherapy, noting that they frequently involve changes to skin, hair, and nails, and reports no new results.

Panitumumab can cause excessive ear hair growth.

This case report describes a 64-year-old man with advanced colorectal cancer developing cutaneous side effects from panitumumab, highlighting the importance of early diagnosis and treatment to improve quality of life and therapy continuation.

This review explores the challenges of treating chronic wounds and highlights regenerative medicine as a promising approach, emphasizing the roles of growth factors, stem cell therapies, and novel regenerative treatments in improving wound healing and tissue regeneration.

This case report details an occurrence of PRIDE syndrome accompanied by lumbosacral hypertrichosis.

This article provides a reference guide for various dermatological terms, treatments, and conditions, but reports no new clinical findings.

This case study describes a 9-year-old girl with a homozygous EGFR gene mutation, presenting with tubulopathy and chronic dermatitis, whose ongoing symptoms and management offer insights into this rare genetic condition.

EGF receptors are crucial for skin cell growth and decrease with age.

This review discusses the classification, pathogenesis, and management of skin, hair, nail, and mucosal changes due to EGFR inhibitors, emphasizing the importance of informing patients to improve therapy compliance.

This mini review reports on papulopustular eruptions linked to classical EGFR inhibitors, MEK inhibitors, and amivantamab, highlighting distinct dermatologic toxicities in each treatment context and exploring underlying mechanisms and management strategies.

This study found that the expression of LRIG1 in Merkel cell carcinoma tumors was associated with improved overall and cancer-specific survival.

In this mouse study, the researchers found that the monoclonal antibody ME1 causes hair follicle inflammation by up-regulating TNFα, which can be reduced by TNFα and interleukin-1 inhibitors.

In this study, researchers found that disrupting EGFR signaling in mice led to increased inflammation and hair follicle damage but that inhibiting the JAK-STAT1 pathway could restore hair growth and skin function.

This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.

This study reports that overexpressing the BMP antagonist noggin in mice inhibits eyelid opening by reducing apoptosis and delaying cell differentiation in the eyelid epithelium.

This study found that spironolactone enhanced the effectiveness of non-DNA-damaging cancer drugs gemcitabine and osimertinib in cancer cell lines and a mouse xenograft model, likely by suppressing the anti-apoptotic protein survivin.

Chemotherapy can cause skin side effects that affect patients' lives, but they can be managed to avoid interrupting cancer treatment.

This review highlights the potential for physical exercise to reduce treatment toxicity and modification rates in patients with metastatic colorectal cancer receiving systemic treatments, suggesting benefits for survival outcomes; it recommends further trials to confirm these findings.

Some lung cancer patients treated with EGFR inhibitors may develop a hair loss condition similar to folliculitis decalvans.